Carregant...
Trastuzumab: updated mechanisms of action and resistance in breast cancer
HER2-postitive breast cancer has the second-poorest prognosis among breast cancer subtypes. One of the most effective targeted therapies for patients with HER2-positive breast cancer is trastuzumab-based. However, primary or acquired resistance to trastuzumab has been a major obstacle in the clinica...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2012-06-01
|
| Col·lecció: | Frontiers in Oncology |
| Matèries: | |
| Accés en línia: | http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00062/full |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|